Exploring bacteriophages as potential tools for combating multi drug-resistant Klebsiella pneumoniae: Isolation,

Rahma E Ali1, Amal S M Abo-Senna1, Rasha A S El-Safty1

  • 1Botany and Microbiology Department, Faculty of Science, Al-Azhar University (Girls Branch), Yossuf Abbas St., P.O. 11754, Cairo, Nasr City, Egypt.

Microbial Pathogenesis
|January 1, 2026
PubMed

Insights

Two novel bacteriophages, RAH1 and RAH2, show strong potential against multidrug-resistant Klebsiella pneumoniae. A phage cocktail demonstrated superior efficacy and specificity for targeted antimicrobial therapy.

Area of Science:

  • Microbiology
  • Virology
  • Genomics

Background:

  • Multidrug-resistant (MDR) Klebsiella pneumoniae poses a significant threat as a cause of hospital-acquired infections.
  • Bacteriophages are emerging as a viable alternative to conventional antibiotics for combating MDR pathogens.

Purpose of the Study:

  • To isolate and characterize novel bacteriophages targeting K. pneumoniae.
  • To evaluate the therapeutic potential of individual phages and a phage cocktail against K. pneumoniae.

Main Methods:

  • Isolation of K. pneumoniae-specific phages from sewage.
  • Morphological, physicochemical, and genomic characterization of isolated phages.
  • Bactericidal activity assessment using killing-curve assays and host-range analysis.

Main Results:

  • Two novel Siphovirus-like phages, RAH1 and RAH2, were identified with genome sizes of 46,784 bp and 59,380 bp, respectively.
  • Phages demonstrated stability at physiological conditions but were sensitive to heat and UV.
  • A phage cocktail exhibited enhanced and prolonged inhibition of K. pneumoniae, lysing 9 of 15 clinical isolates with high specificity.
  • Genomic analysis revealed no antimicrobial resistance or virulence genes; RAH2 is strictly lytic, while RAH1 is temperate.

Conclusions:

  • The characterized bacteriophages, particularly the strictly lytic RAH2, show promise as therapeutic agents against K. pneumoniae.
  • Phage therapy offers a targeted approach to combat MDR infections, minimizing disruption to the host microbiota.